ClinicalTrials.gg
RecruitingNCT07618299Updated Sep 25, 2026

Evaluation of the Excretion of Fosfomycin Into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women

A Phase 4 interventional study of ZTI-01 in Healthy Lactating Women, sponsored by Meitheal Pharmaceuticals, Inc.. Recruiting at 1 site in South Africa. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Meitheal Pharmaceuticals, Inc. · Phase 4, Interventional, and Other

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Sep 25, 2026Now RecruitingFirst site in South Africa+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Evaluation of the Excretion of Fosfomycin into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women

Read the detailed description

Evaluation of the Excretion of Fosfomycin into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women

02

Conditions studied

  • Healthy Lactating Women
03

In context

Lead sponsor

This is the only study on the registry with Meitheal Pharmaceuticals, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 45 years of age inclusive, at the time of signing the .
  2. Participant is a healthy lactating female, who is actively breastfeeding (including baby to breast, bottle feeding mother's expressed breast milk) and is at least 12 weeks postpartum of a healthy term (≥ 37 weeks gestational age) newborn infant (no medical complications) and not more than 1 years postpartum. Lactation must be well established prior to the day of admission to inpatient unit.
  3. Participant is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead at screening.
  4. Participant is willing to temporarily discontinue breastfeeding their infant and discard all their breast milk for 5 consecutive days, including (day of admission to inpatient unit (Day -1), day of dosing while in the inpatient unit (Day 1), and 3 consecutive days after dose (including the day of discharge from the inpatient unit and 2 days at home; Days 2 to 4); and willing to store sufficient amount of breastmilk (e.g., breast milk pumped and stored in freezer before the day of admission), and/or infant formula to feed infant during these 5 consecutive days.
  5. Participant must not be in the process of weaning before admission to inpatient unit and have maintained an adequate breast milk supply (according to Investigator discretion) with regularly pumping or routine breastfeeding (e.g., pumping or feeding 3-4 times a day) at admission.
  6. Participant has a (BMI) within the range 18 to 35 kg/m2 (inclusive)
  7. Participant is either sexually inactive (abstinent) or, if sexually active, must agree to use/practice one of the acceptable methods listed in Section 10.3 beginning before or during the screening period prior to the first dose, throughout the inpatient stay, and for 3 days following the dose.
  8. Signed informed consent as described in Section 10.1.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  9. Willingness to follow protocol defined restrictions and Investigator/staff instructions and protocol procedures.
  10. Agrees to use only the emollient or nipple cream recommended by the investigator for use during the sampling period, if needed.

Exclusion criteria

Exclusion Criteria:

  1. Participant is pregnant or plans to become pregnant during the course of the study.
  2. Sensitivity to any of the study interventions, or components thereof, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
  3. History or presence of cardiovascular, respiratory, psychiatric, metabolic, hepatic, renal, gastrointestinal, endocrinological, hematological, oncological, or neurological disorders determined to be by the Investigator.
  4. History or presence of any condition that in the opinion of the Investigator would constitute a risk when taking the study intervention or interfere with the interpretation of data.
  5. History or presence of drug or alcohol abuse or current alcohol use > 21 units of alcohol per week (1 unit is equal to approximately 330 mL of beer, 1 small glass [200 mL] of wine, or 1 measure [25 mL] of spirits).
  6. History or regular use of tobacco- or nicotine-containing products within 6 months prior to screening with the exception of casual smokers (i.e., \< 5 cigarettes per week).
  7. Has history of mastitis within 30 days, breast cancer and/or has had a mastectomy or lumpectomy with the exception of a benign fibroma or lipoma removal at the investigator's discretion; and/or a clinically significant abnormality observed in either breast during a clinical breast exam at Screening or Admission (Day -1).
  8. Past or intended use of prescription medication within 14 days or over-the-counter medication including herbal medications within 7 days prior to dosing (apart from vitamin/mineral supplements or occasional paracetamol).
  9. Current enrollment or past participation in another study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within 90 days or 5 half-lives (whichever is longer) before planned first dose of study intervention in this clinical study.
  10. Positive drug/alcohol screen at screening or Day -1. At screening visit, in case of a positive result the urine screen for drugs of abuse may be repeated once at the discretion of the Investigator.
  11. Evidence of (HIV) infection and/or positive human HIV antibodies at screening; positive test results for surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or virus (HCV Ab) antibodies at screening.
  12. Positive pregnancy test at screening or Day -1.
  13. Clinically significant vital signs, findings, or laboratory abnormalities, including ≤ 50 mL/min.
  14. Has history of breast implants, breast augmentation, or breast reduction surgery.
  15. Unwilling to abstain from alcohol for 48 hours prior to dosing through the duration of confinement.
  16. Employees or close relatives of the contract service providers, the sponsor, 3rd party vendors or affiliates of the above mentioned parties.
  17. Vulnerable participants (e.g., persons in detention).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Other
    ZTI-01

    Participants will receive single intravenous dose of ZTI-01 (6 g)

    Drug: ZTI-01

Interventions

  • DrugZTI-01

    Participants will receive a single intravenous dose of ZTI-01 (6 g)

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve for drug concentrations in breast milk from time 0 to 24 hours (AUC0-24h,milk)

    To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose

    Time frame: 0-24 hours post dose

  2. Maximum observed drug concentration in breast milk (Cmax,milk)

    To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose

    Time frame: 0-24 hours post dose

  3. Time to reach the maximum observed drug concentration in breast milk (Tmax,milk)

    To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose

    Time frame: 0-24 hours post dose

  4. Average drug concentration in breast milk (Cave,milk), calculated as AUC₀-24h, milk divided by Tau (τ)

    To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose

    Time frame: 0-24 hours post dose

  5. Total amount of drug in breast milk over a period of 24 hours (Ammilk, mg/day) following a single dose

    To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose

    Time frame: 0-24 hours post dose

Secondary outcomes

  1. Estimated daily infant dosage (EDID, mg/kg/day)

    To estimate daily infant dose of ZTI-01 via breast milk

    Time frame: 0-24 hours post dose

  2. Relative infant dose (RID, %)

    To estimate daily infant dose of ZTI-01 via breast milk

    Time frame: 0-24 hours post dose

  3. Adverse event (AE) assessments

    To assess the safety and tolerability of ZTI-01 in healthy lactating women

    Time frame: Baseline (Day 1) to End of Study (Day 4)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: start Jul 2026 → Sep 2026, primary completion Aug 2027 → Sep 2027 and completion Aug 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
Jun 1, 2026
StartActual
Sep 22, 2026was Jul 2026
Primary completionEst.
Sep 2027was Aug 2027
CompletionEst.
Sep 2027was Aug 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
1 site added — first site in South Africa
Show site
  • FARMOVS (Pty) Ltd · Bloemfontein, South Africa
Sep 25, 2026
Start date
Jul 2026→Sep 22, 2026 (actual)
Sep 25, 2026
Primary completion
Aug 2027→Sep 2027
Sep 25, 2026
Study completion
Aug 2027→Sep 2027
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in South Africa
    Show site
    • FARMOVS (Pty) Ltd · Bloemfontein, South Africa
    Start date Jul 2026→Sep 22, 2026 (now actual)
    Primary completion Aug 2027→Sep 2027
    Study completion Aug 2027→Sep 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07618299
Lead sponsor
Meitheal Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 22, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Meitheal Pharmaceuticals, Inc. Meitheal Pharmaceuticals, Inc.
Contact
info@meithealpharma.com
(224) 443-4617

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosfomycin sodium

Start the discussion